CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

CELLECTRA® 2000Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (6)

Name (Synonyms) Correlation
drug1152 INO-4800 Wiki 1.00
drug2518 Thymosin+standard treatment Wiki 0.71
drug2185 Saline-sodium citrate (SSC) buffer Wiki 0.71
drug3013 standard treatment Wiki 0.71
drug1729 PD-1 blocking antibody+standard treatment Wiki 0.71
drug2880 mRNA-1273 Wiki 0.50

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.07
D018352 Coronavirus Infections NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers

This is an open-label trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA® 2000 device in healthy adult volunteers.

NCT04336410 Coronavirus Infection Drug: INO-4800 Device: CELLECTRA® 2000
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Measure: Percentage of Participants with Adverse Events (AEs)

Time: Baseline up to Week 52

Measure: Percentage of Participants with Administration (Injection) Site Reactions

Time: Day 0 up to Week 52

Measure: Percentage of Participants with Adverse Events of Special Interest (AESIs)

Time: Baseline up to Week 52

Measure: Change from Baseline in Antigen-Specific Binding Antibody Titers

Time: Baseline up to Week 52

Measure: Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response

Time: Baseline up to Week 52

2 A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers

This is a phase I/IIa trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA® 2000 device in healthy adults aged 19 to 64 years in Republic of Korea. INO- 4800 contains the plasmid pGX9501, which encodes for the full length of the Spike glycoprotein of SARS-CoV-2. The primary objective of this trial is to evaluate the tolerability, safety, and immunogenicity of INO-4800 administered by ID injection followed by EP in healthy adults in the Part A and Part B. Enrollment into Part A, and Part B will proceed sequentially.

NCT04447781 Coronavirus Infection SARS-CoV 2 Biological: INO-4800 Device: CELLECTRA® 2000 Other: Saline-sodium citrate (SSC) buffer
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Percentage of participants with seroconversion of SARS-CoV-2 Spike glycoprotein antigen-specific antibody titers from baseline by binding assays [Immunogenicity] Incidence of adverse events among participants during the study period [Safety and Tolerability] Percentage of Participants with Administration (Injection) Site Reactions [Safety and Tolerability] Incidence of Adverse Events of Special Interest (AESIs) among participants during the study period [Safety and Tolerability]

Measure: Primary Outcome Measures

Time: Baseline up to Week 52

No related HPO nodes (Using clinical trials)